Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

The Faculty of Medicine - Immunology and Cancer Research: Naor David


 Last updated June 2021 - School of Public Health

List of Publications

(1) Murai T, Kawashima H, Naor D. Editorial: Cell-Cell and Cell-Matrix Adhesion in Immunobiology and Cancer. Front Immunol 2020;10.

(2) Pinner E, Gruper Y, Ben Zimra M, Kristt D, Laudon M, Naor D, et al. CD44 Splice Variants as Potential Players in Alzheimer's Disease Pathology. J Alzheimer's Dis 2017;58(4):1137-1149.

(3) Beider K, Naor D, Voevoda V, Ostrovsky O, Bitner H, Rosenberg E, et al. Dissecting the mechanisms involved in anti-human T-lymphocyte immunoglobulin (ATG)-induced tolerance in the setting of allogeneic stem cell transplantation - potential implications for graft versus host disease. Oncotarget 2017;8(53):90748-90765.

(4) Barzilay R, Ventorp F, Segal-Gavish H, Aharony I, Bieber A, Dar S, et al. CD44 Deficiency Is Associated with Increased Susceptibility to Stress-Induced Anxiety-like Behavior in Mice. J Mol Neurosci 2016;60(4):548-558.

(5) Naor D. Editorial: Interaction between hyaluronic acid and its receptors (CD44, RHAMM) regulates the activity of inflammation and cancer. Front Immunol 2016;7(FEB).

(6) Assayag-Asherie N, Sever D, Bogdani M, Johnson P, Weiss T, Ginzberg A, et al. Can CD44 be a mediator of cell destruction? the challenge of type 1 diabetes. PLoS ONE 2015;10(12).

(7) Gesundheit B, Ashwood P, Keating A, Naor D, Melamed M, Rosenzweig JP. Therapeutic properties of mesenchymal stem cells for autism spectrum disorders. Med Hypotheses 2015;84(3):169-177.

(8) Gesundheit B, Rosenzweig JP, Naor D, Lerer B, Zachor DA, Procházka V, et al. Immunological and autoimmune considerations of Autism Spectrum Disorders. J Autoimmun 2013;44:1-7.

(9) Girbl T, Hinterseer E, Grössinger EM, Asslaber D, Oberascher K, Weiss L, et al. CD40-mediated activation of chronic lymphocytic leukemia cells promotes their CD44-dependent adhesion to hyaluronan and restricts CCL21-induced motility. Cancer Res 2013;73(2):561-570.

(10) Shimony O, Nagler A, Gellman YN, Refaeli E, Rosenblum N, Eshkar-Sebban L, et al. Anti-T lymphocyte globulin (ATG) induces generation of regulatory T cells, at least part of them express activated CD44. J Clin Immunol 2012;32(1):173-188.

(11) Turley EA, Naor D. RHAMM and CD44 peptides-analytic tools and potential drugs. Front Biosci 2012;17(5):1775-1794.

(12) Kahaly GJ, Shimony O, Gellman YN, Lytton SD, Eshkar-Sebban L, Rosenblum N, et al. Regulatory T-cells in Graves' orbitopathy: Baseline findings and immunomodulation by anti-T lymphocyte globulin. J Clin Endocrinol Metab 2011;96(2):422-429.

(13) Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV. Involvement of CD44, a Molecule with a Thousand Faces, in Cancer Dissemination. Hyaluronan in Cancer Biology; 2009. p. 127-146.

(14) Vagima Y, Avigdor A, Goichberg P, Shivtiel S, Tesio M, Kalinkovich A, et al. MT1-MMP and RECK are involved in human CD34+ progenitor cell retention, egress, and mobilization. J Clin Invest 2009;119(3):492-503.

(15) Wallach-Dayan SB, Rubinstein AM, Hand C, Breuer R, Naor D. DNA vaccination with CD44 variant isoform reduces mammary tumor local growth and lung metastasis. Mol Cancer Ther 2008;7(6):1615-1623.

(16) Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 2008;18(4):260-267.

(17) Gonen E, Nedvetzki S, Naor D, Shpigel NY. CD44 is highly expressed on milk neutrophils in bovine mastitis and plays a role in their adhesion to matrix and mammary epithelium. Vet Res 2008;39(3).

(18) Weiss L, Botero-Anug AM, Hand C, Slavin S, Naor D. CD44 gene vaccination for insulin-dependent diabetes mellitus in non-obese diabetic mice. Isr Med Assoc J 2008;10(1):20-25.

(19) Garin T, Rubinstein A, Grigoriadis N, Nedvetzki S, Abramsky O, Mizrachi-Koll R, et al. CD44 variant DNA vaccination with virtual lymph node ameliorates experimental autoimmune encephalomyelitis through the induction of apoptosis. J Neurol Sci 2007;258(1-2):17-26.

(20) Sebban LE, Ronen D, Levartovsky D, Elkayam O, Caspi D, Aamar S, et al. The involvement of CD44 and its novel ligand galectin-8 in apoptotic regulation of autoimmune inflammation. J Immunol 2007;179(2):1225-1235.

(21) Golan I, Nedvetzki S, Golan I, Eshkar-Sebban L, Levartovsky D, Elkayam O, et al. Expression of extra trinucleotide in CD44 variant of rheumatoid arthritis patients allows generation of disease-specific monoclonal antibody. J Autoimmun 2007;28(2-3):99-113.

(22) Naor D, Nedvetzki S, Walmsley M, Yayon A, Turley EA, Golan I, et al. CD44 involvement in autoimmune inflammations: The lesson to be learned from CD44-targeting by antibody or from knockout mice. Ann New York Acad Sci 2007;1110:233-247.

(23) Nedvetzki S, Gonen E, Assayag N, Reich R, Williams RO, Thurmond RL, et al. Erratum: RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: A different interpretation of redundancy (Proceedings of the National Academy of Sciences of the United States of America (December 28, 2004) 101, 52 (18081-18086)). Proc Natl Acad Sci U S A 2005;102(4):1263.

(24) Naor D, Nedvetzki S, Assayag N, Thurmond RL, Huang J-, Turley EA. The mechanism of molecular redundancy in autoimmune inflammation in the context of CD44 deficiency. Ann New York Acad Sci 2005;1050:52-63.

(25) Nedvetzki S, Gonen E, Assayag N, Reich R, Williams RO, Thurmond RL, et al. RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: A different interpretation of redundancy. Proc Natl Acad Sci U S A 2004;101(52):18081-18086.

(26) Avigdor A, Goichberg P, Shivtiel S, Dar A, Peled A, Samira S, et al. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood 2004;103(8):2981-2989.

(27) Naor D, Nedvetzki S. CD4 in rheumatoid arthritis. Arthritis Res Ther 2003;5(3):105-115.

(28) Ursø B, Ilondo MM, Holst PA, Christoffersen CT, Ouwens M, Giorgetti S, et al. IRS-4 mediated mitogenic signalling by insulin and growth hormone in LB cells, a murine T-cell lymphoma devoid of IGF-I receptors. Cell Signal 2003;15(4):385-394.

(29) Nedvetzki S, Golan I, Assayag N, Gonen E, Caspi D, Gladnikoff M, et al. A mutation in a CD44 variant of inflammatory cells enhances the mitogenic interaction of FGF with its receptor. J Clin Invest 2003;111(8):1211-1220.

(30) Guy R, Yefenof E, Naor D, Dorogin A, Zilberman Y. CD44 co-stimulates apoptosis in thymic lymphomas and T cell hybridomas. Cell Immunol 2002;216(1-2):82-92.

(31) Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. Crit Rev Clin Lab Sci 2002;39(6):527-579.

(32) Wallach-Dayan SB, Grabovsky V, Moll J, Sleeman J, Herrlich P, Alon R, et al. CD44-dependent lymphoma cell dissemination: A cell surface CD44 variant, rather than standard CD44, supports in vitro lymphoma cell rolling on hyaluronic acid substrate and its in vivo accumulation in the peripheral lymph nodes. J Cell Sci 2001;114(19):3463-3477.

(33) Batya Wallach S, Friedmann A, Naor D. The CD44 receptor of the mouse LB T-cell lymphoma: Analysis of the isoform repertoire and ligand binding properties by reverse-transcriptase polymerase chain reaction and antisense oligonucleotides. Cancer Detect Prev 2000;24(1):33-45.

(34) Weiss L, Slavin S, Reich S, Cohen P, Shuster S, Stern R, et al. Induction of resistance to diabetes in non-obese diabetic mice by targeting CD44 with a specific monoclonal antibody. Proc Natl Acad Sci U S A 2000;97(1):285-290.

(35) Rochman M, Moll J, Herrlich P, Wallach SB, Nedvetzki S, Sionov RV, et al. The CD44 receptor of lymphoma cells: Structure-function relationships and mechanism of activation. Cell Adhes Commun 2000;7(4):331-347.

(36) Nedvetzki S, Walmsley M, Alpert E, Williams RO, Feldmann M, Naor D. CD44 involvement in experimental collagen-induced arthritis (CIA). J Autoimmun 1999;13(1):39-47.

(37) Sionov RV, Naor D. Calcium- and calmodulin-dependent PMA-activation of the CD44 adhesion molecule. Cell Adhes Commun 1998;6(6):503-523.

(38) Naor D, Vogt Sionov R, Zahalka M, Rochman M, Holzmann B, Ish-Shalom D. Organ-specific requirements for cell adhesion molecules during lymphoma cell dissemination. Curr Top Microbiol Immunol 1997;231:143-166.

(39) Ish-Shalom D, Christoffersen CT, Vorwerk P, Sacerdoti-Sierra N, Shymko RM, Naor D, et al. Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia 1997;40(SUPPL. 2):S25-S31.

(40) Sionov RV, Naor D. Hyaluronan-independent lodgment of CD44+ lymphoma cells in lymphoid organs. Int J Cancer 1997;71(3):462-469.

(41) Naor D, Sionov RV, Ish-Shalom D. CD44: Structure, function, and association with the malignant process. ADV CANCER RES 1997;71:241-319.

(42) Gosslar U, Jonas P, Luz A, Lifka A, Naor D, Hamann A, et al. Predominant role of α4-integrins for distinct steps of lymphoma metastasis. Proc Natl Acad Sci U S A 1996;93(10):4821-4826.

(43) Rocha M, Krüger A, Umansky V, Von Hoegen P, Naor D, Schirrmacher V. Dynamic expression changes in vivo of adhesion and costimulatory molecules determine load and pattern of lymphoma liver metastasis. CLIN CANC RES 1996;2(5):811-820.

(44) Urs⊘ B, Christoffersen CT, Tornqvist H, De Meyts P, Ouwens M, Vlahos C, et al. Mitogenic signalling by insulin in a T-cell lymphoma, the LB cell line, devoid of IGF-I receptors: Evidence for the lack of involvement of the RAS-MAP kinase pathway and for a possibly novel IRS-like molecule. Exp Clin Endocrinol Diabetes 1996;104:52-53.

(45) Stock R, Naor D. Induction of an autoimmune response against syngeneic lymphoma cells by immunogenic 64-kDa protein isolated from normal blast cells of BALB/c mice. Cancer Immunol Immunother 1995;40(1):48-56.

(46) Zahalka MA, Okon E, Gosslar U, Holzmann B, Naor D. Lymph node (but not spleen) invasion by murine lymphoma is both CD44- and hyaluronate-dependent. J Immunol 1995;154(10):5345-5355.

(47) ISH‐SHALOM D, TZIVION G, CHRISTOFFERSEN CT, URSØ B, DE MEYTS P, NAOR D. Mitogenic Potential of Insulin on Lymphoma Cells Lacking IGF‐1 Receptor. Ann New York Acad Sci 1995;766(1):409-414.

(48) Zahalka MA, Naor D. β2-lntegrin dependent aggregate formation between LB T cell lymphoma and spleen cells: Assessment of correlation with spleen invasiveness. Int Immunol 1994;6(6):917-924.

(49) Zahalka MA, Okon E, Naor D. Blocking lymphoma invasiveness with a monoclonal antibody directed against the β-chain of the leukocyte adhesion molecule (CD18). J Immunol 1993;150(10):4466-4477.

(50) Sharon R, Pillemer G, Ish‐Shalom D, Kalman R, Ziv E, Berry EM, et al. Insulin dependence of murine T‐cell lymphoma. II. Insulin‐deficient diabetic mice and mice fed low‐energy diet develop resistance to lymphoma growth. Int J Cancer 1993;53(5):843-849.

(51) Naor D. Bifunctional T cell clones challenge the traditional compartmentalization concept of the immune system. ARCH IMMUNOL THER EXP 1992;40(1):67-70.

(52) Naor D. A different outlook at the phenotype-function relationships of T cell subpopulations: Fundamental and clinical implications. Clin Immunol Immunopathol 1992;62(2):127-132.

(53) Sharon R, Naor D. Experimental model of autoimmune hemolytic anemia induced in mice with levodopa by intraperitoneal injection or oral feeding. Int J Immunopharmacol 1992;14(7):1241-1247.

(54) Pillemer G, Lugasi‐Evgi H, Scharovsky G, Naor D. Insulin dependence of murine lymphoid T‐cell leukemia. Int J Cancer 1992;50(1):80-85.

(55) Zahalka MA, Naor D. Inflammatory response induced with an isolated syngeneic activation antigen shared by normal lymphoblasts and YAC lymphoma cells. Clin Immunol Immunopathol 1991;59(1):72-88.

(56) NAOR D, ESSERY G, TARCIC N, KAHAN M, FELDMANN M. Regulatory Interactions among Autologous T Cell Clones Human Bifunctional T Cell Clones Regulate the Activity of an Autologous T Cell Clone. Ann New York Acad Sci 1991;636(1):135-146.

(57) Duke-Cohan JS, Rubinow A, Hirt R, Naor D. The reaction against autologous lymphoblasts as an indicator of lymphocyte hyperreactivity in rheumatoid arthritis. Clin Immunol Immunopathol 1990;54(2):298-308.

(58) Naor D, Essery G, Tarcic N, Kahan M, Feldmann M. Interactions between autologous T cell clones. Cell Immunol 1990;128(2):490-502.

(59) Naor D, Essery G, Taroc N, Kahan M, Lamb JR, Feldmann M. Specific Interactions between a Human CD4+ Clone and Autologous CD4+ Bifunctional Immunoregulatory Clones. Immunol Rev 1990;116(1):63-83.

(60) Lugasi H, Hajos S, Murphy JR, Strom TB, Nichols J, Peñarroja C, et al. Murine spontaneous T‐cell leukemia constitutively expressing IL‐2 receptor—a model for human T‐cell malignancies expressing IL‐2 receptor. Int J Cancer 1990;45(1):163-167.

(61) Alvarez E, Mongini C, Waldner CI, Fenandez TB, Naor D, Hajos SE. The inter-relationships between spontaneous murine T cell leukaemia LB and the immune system: LB is a nonimmunogenic tumor in its syngeneic host. J Exp Clin Cancer Res 1989;8(4):181-192.

(62) Sharon R, Naor D. Experimental model of autoimmune hemolytic anemia induced in mice with Levodopa. Clin Immunol Immunopathol 1989;52(2):160-172.

(63) Tarcic N, David CS, Naor D. Auto-delayed-type hypersensitivity induced in immunodeficient mice with modified self-antigens. V. Cellular autoreactivity directed against self-H-2D(d) subregion mediates the inflammatory responses. Immunology 1989;67(2):184-190.

(64) Naor D, Essery G, Kahan M, Feldmann M. T-cell clone anti-clone interactions. Effects on suppressor and helper activities. J Autoimmun 1989;2(SUPPL. 1):3-14.

(65) Naor D, Essery G, Tarcic N, De Berardinis P, Kahan M, Feldmann M. Autoreactivity against class I or class II antigens - Immunological downregulation mechanism? Bull Inst Pasteur 1989;87(1):3-17.

(66) DUKE‐COHAN JS, HIRT R, ROTTEM M, BEN‐ZVI A, RUBINOW A, NAOR D. Use of an autologous reaction in vitro to assess contributions of T and B lymphocytes to immune hyperreactivity of atopics. Clin Exp Allergy 1989;19(2):163-168.

(67) KLEIN I, NAOR D. Self‐Reactive Delayed Type Hypersensitivity Induced in Mice by Syngeneic Lymphoblasts: III. Immunological Characterization of the Small and Large Antigens of the Blast Cells. Scand J Immunol 1988;27(4):385-392.

(68) Klein I, Naor D. Autoinflammatory response to self-antigens of lymphoblasts. Isr J Med Sci 1988;24(7):373-374.

(69) Sharon R, Giloh H, Naor D. Experimental autoimmune anemia induced with haptenated syngeneic mouse red blood cells and low dose X-irradiation. Clin Immunol Immunopathol 1988;47(3):310-322.

(70) KLEIN I, KLEIN BY, NAOR D. Self‐Reactive Delayed Type Hypersensitivity Induced in Mice by Syngeneic Lymphoblasts: II. Isolation of Two Distinct Lymphoblast Antigens, One of Which Reacts (or Cross‐Reacts) with Anti‐H‐2Dd Monoclonal Antibody. Scand J Immunol 1988;27(2):209-222.

(71) Naor D. Suppressor cells and human malignancy. Clin Immunol Newsl 1987;8(5):65-69.

(72) Duke-Cohan JS, Hirt R, Dahan A, Naor D. On the immune reaction to autologous human lymphoblasts: Evidence for the stimulation by activating factors rather than induction by autoantigens. Clin Immunol Immunopathol 1987;43(2):229-242.

(73) Naor D, Duke-Cohan JS. Suppressor cells and malignancy. I. Suppressor macrophages and suppressor T cells in experimental animals. Adv Immun Cancer Ther 1986;2:1-129.

(74) Kelley VE, Naor D, Tarcic N, Gaulton GN, Strom TB. Anti-interleukin 2 receptor antibody suppresses delayed-type hypersensitivity to foreign and syngeneic antigens. J Immunol 1986;137(7):2122-2124.

(75) Tarcic N, Naor D. The genetic control of syngeneic delayed type hypersensitivity (syn-DTH). Immunogenetics 1986;24(2):131-134.

(76) Hutchings P, Naor D, Cooke A. Effects of low doses of cyclophosphamide and low doses of irradiation on the regulation of induced erythrocyte autoantibodies in mice. Immunology 1985;54(1):97-104.

(77) Naor D, Langer A. Analysis of the cyclosporine mechanism in an immunological autoreactive model of delayed-type hypersensitivity. Transplant Proc 1985;17(6):2706-2708.

(78) Klein I, Naor D. Self Reactive Delayed Type Hypersensitivity (DTH) Induced in Mice by Syngeneic Lymphoblasts. Immunobiology 1985;169(1):45-59.

(79) Naor D, Tarcic N, Baler R. Control of in vivo immunological autoreactivities with suppressive T cell factor derived from a hybridoma cell line. Transplant Proc 1985;17(6):2617-2621.

(80) Langer A, Rosenmann E, Naor D. The effect of cyclosporin on murine autoreactive delayed type hypersensitivity induced with syngeneic lymphoblasts. Immunopharmacology 1985;10(3):147-155.

(81) Duke-Cohan JS, Weinberg H, Sharon R, Naor D. Immunological function in osteoporosis. Clin Immunol Immunopathol 1985;35(1):125-129.

(82) Sharon R, Naor D. The isolation of immunogenic molecular entities from immunogenic and nonimmunogenic tumor homogenates by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Cancer Immunol Immunother 1984;18(3):203-208.

(83) Klein BY, Frenkel S, Naor D. Isolated soluble fractions from the murine B16 melanoma induce primary in vitro syngeneic antitumor responses. Cancer Immunol Immunother 1984;18(3):195-202.

(84) TARCIC N, BALER R, NAOR D. Auto‐Delayed‐Type Hypersensitivity Induced in Immunodeficient Mice withModified Self‐Antigens: III. Suppressive T‐Cell Factor Controls the Autoreactivity against Self‐Antigens. Scand J Immunol 1984;20(5):389-401.

(85) TARCIC N, KLEIN BY, NAOR D. Auto‐Delayed‐Type Hypersensitivity Induced in Immunodeficient Mice with Modified Self‐Antigens: IV. Characterization of the Suppressive T‐Cell Factor that Controls the Autoreactivity against Self‐Antigens. Scand J Immunol 1984;20(5):403-411.

(86) Klein BY, Frenkel S, Naor D. Isolation of murine melanoma antigens crossreactive with human melanoma antigens, detected by cell mediated cytotoxicity. Fed Proc 1984;43(6).

(87) TARCIC N, SHARON R, ROSENMANN E, NAOR D. Auto‐Delayed‐Type Hypersensitivity Induced in Immunodeficient Mice with Syngeneic Modified Self‐Antigens: II. Suppressor T Cells Control the Autoimmune Response. Scand J Immunol 1984;19(2):111-121.

(88) Adler A, Stein JA, Kedar E, Naor D, Weiss DW. Intralesional injection of interleukin-2 — Expanded autologous lymphocytes in melanoma and breast cancer patients: A pilot study. J Biol Response Modif 1984;3(5):491-500.

(89) Naor D. Coexistence of immunogenic and suppressogenic epitopes in tumor cells and various types of macromolecules. Cancer Immunol Immunother 1983;16(1):1-10.

(90) Ahituv A, Naor D, Sharon R, Tarcic N, Klein BY. Immunogenicity of subcellular fractions and molecular species of MuLV-induced tumors - III. Stimulation of syngeneic antitumor responses by subcellular fractions and molecular species of moloney virus-induced tumors in CBA and a mice. Cancer Immunol Immunother 1982;14(1):16-26.

(91) Tarcic N, Naor D. Delayed‐type hypersensitivity induced in immunodeficient mice with syngeneic modified self antigens: a suggestive model of autoimmune response. Eur J Immunol 1982;12(11):961-966.


(93) Klein BY, Sharon R, Tarcic N, Naor D. Induction of Antitumor Reactive Cells or Suppressor Cells by Different Molecular Species Isolated from the Same Nonimmunogenic Tumor. Immunobiology 1982;163(1):7-21.

(94) Klein BY, Devens B, Deutsch O, Ahituv A, Frenkel S, Kobrin BJ, et al. Isolation of immunogenic and suppressogenic determinants of the nonimmunogenic YAC tumor and the change in its immunogenic repertoire after in vitro cultivation. Transplant Proc 1981;13(1):790-797.

(95) Kobrin BJ, Naor D, Klein BY. Immunogenicity of subcellular fractions and molecular species of MuLV-induced tumors. II. Stimulation of syngeneic anti-tumor cell-mediated immune responses by subcellular fractions and molecular species of the Rauscher-virus-induced RBL5 tumor. J Immunol 1981;126(5):1874-1882.

(96) Devens B, Deutsch O, Avraham Y, Naor D. Immune Response to Weakly Immunogenic Virally Induced Tumors. IX. Mice Injected with the in vitro Variant of YAC Tumor (YAC-1) Resist Lethal Doses of the Tumorgenic YAC Cells. Immunobiology 1981;159(4-5):432-443.

(97) Naor D. Unresponsiveness to Modified Self Antigens ‐ A Censorship Mechanism Controlling Autoimmunity? Immunol Rev 1980;50(1):187-226.

(98) Leshem B, Naor D. Studies on the immune response to fixed antigens. IV. Recall of immunologic memory with fixed antigens. Isr J Med Sci 1980;16(1):25-32.

(99) Devens B, Naor D. Immune responses to weakly immunogenic virally induced tumors. VI. Comparison of the immune response of the hybrid to the immune responses of the parents reveals 'hybrid responsiveness' effect. J Immunol 1980;125(3):988-994.

(100) Deutsch O, Devens B, Naor D. Immune responses to weakly immunogenic murine-leukemia-virus-induced tumors. VII. Kinetic studies on various parameters of effects induced with suppressor cells. Isr J Med Sci 1980;16(7):530-537.

(101) Deutsch O, Devens B, Naor D. Immune responses to weakly immunogenic murine-leukemia-virus-induced tumors. VIII. Characterization of suppressor cells. Isr J Med Sci 1980;16(7):538-544.

(102) Klein BY, Frenkel S, Ahituv A, Naor D. Immunogenicity of subcellular fractions and molecular species of MuLV-induced tumors. I. screening of immunogenic components by isopycnic ultracentrifugation and polyacrylamide electrophoresis of a tumor homogenate. J Immunol Methods 1980;38(3-4):325-341.

(103) Naor D. Suppressor cells: Permitters and promoters of malignancy? Adv Cancer Res 1979;29(C):45-125.

(104) Devens B, Naor D. Immune responses to weakly immunogenic virally induced tumors. III. Genetically unrestricted cytolysis of allogeneic tumor target cells. J Immunol 1979;122(4):1397-1401.

(105) Ashman RF, Naor D. Membrane defects of the tolerant B cell. I. Failure of antigen-induced capping. Cell Immunol 1979;44(2):314-328.

(106) Devens B, Naor D, Kedar E. Immune response to weakly immunogenic virally induced tumors iv dissociated recognition of H-2 and tumor associated antigens: IV dissociated recognition of h 2 and tumor associated antig4ens. Transplantation 1979;28(5):389-395.

(107) Devens B, Schochot L, Naor D. Immune responses to weakly immunogenic virally induced tumors. V. Short in vitro cultivation of YAC changes its antigenic properties. Cell Immunol 1979;44(2):442-453.

(108) Leshem B, Naor D. Studies on the immune response to fixed antigens. III. Induction of helper function for antibody-dependent cellular cytotoxicity responses. J Immunol 1978;121(2):401-408.

(109) Leshem B, Naor D. Cellular assay for measuring anti-erythrocyte antibody responses. J Immunol Methods 1978;20(C):263-275.

(110) Devens B, Galili N, Deutsch O, Naor D, Klein E. Immune responses to weakly immunogenic virally induced tumors II. Suppressive effects of the in vivo carried tumor YAC. Eur J Immunol 1978;8(8):573-578.

(111) Galili N, Devens B, Naor D, Becker S, Klein E. Immune responses to weakly immunogenic virally induced tumors I. Overcoming low responsiveness by priming mice with a syngeneic in vitro tumor line or allogeneic cross‐reactive tumor. Eur J Immunol 1978;8(1):17-22.

(112) Naor D, O'Toole C. Cryopreservation of immunological memory and other lymphoid cell functions. J Immunol Methods 1977;16(4):361-370.

(113) Naor D, Kahan M. Studies on the immune response to fixed antigens. II. Optimal conditions for inducing and eliciting helper function by fixed antigens and the mechanism responsible for this effect. Isr J Med Sci 1977;13(6):561-576.

(114) Naor D, Galili N. Immune response to chemically modified antigens. Prog Allergy 1977;Vol. 22:107-146.

(115) Naor D, Bonavida B, Walford RL. Autoimmunity and aging: the age related response of mice of a long lived strain to trinitrophenylated syngeneic mouse red blood cells. J Immunol 1976;117(6):2204-2208.

(116) Kahan M, Berman Goldman R, Salton R, Naor D. Studies on the immune response to fixed antigens. Preferential induction of helper function with heavily trinitrophenylated sheep erythrocytes, and glutaraldehyde treated sheep erythrocytes. J Immunol 1976;117(1):16-22.

(117) Kedar E, Unger E, Galili N, Klein G, Asjo B, Bonavida B, et al. Immunogenicity of tumor cells modified by trinitrobenzene suflonic acid (TNBS). Prog Clin Biol Res 1976;9:109-121.

(118) Galili N, Naor D, Åsjö B, Klein G. Induction of immune responsiveness in a genetically low‐responsive tumor‐host combination by chemical modification of the immunogen. Eur J Immunol 1976;6(7):473-476.

(119) Naor D, Bonavida B, Robinson RA, Shibata IN, Percy DE, Chia D, et al. Immune response of New Zealand mice to trinitrophenylated syngeneic mouse red cells. Eur J Immunol 1976;6(11):783-789.

(120) Naor D, Berman-Goldman R, Kahan M, Goldfisher H, Laskov R, Simon E, et al. Induction of hapten recognizing helper function by heavily trinitrophenylated sheep erythrocytes. Adv Exp Med Biol 1976;66:253-260.

(121) Naor D, Falkenberg F, Saltoun R. Proceedings: Mouse immune response to trinitrophenylated red cells. Isr J Med Sci 1975;11(12):1377-1378.

(122) Naor D, Saltoun R, Falkenberg F. Lack of requirement for thymocytes for efficient antibody formation to trinitrophenylated mouse red cells in mice: Role for thymocytes in suppression of the immune response. Eur J Immunol 1975;5(3):220-223.

(123) Zolla S, Naor D, Tanapatchaiyapong P. Cellular basis of immunodepression in mice with plasmacytomas. J Immunol 1974;112(6):2068-2076.

(124) Zolla S, Naor D. Restoration of immune competence in tolerant mice by parabiosis to normal mice. J Exp Med 1974;140(5):1421-1426.

(125) Sulitzeanu D, Morecki S, Naor D. Specific interactions of antigen with cells studied by means of rosette formation. Isr J Med Sci 1974;10(11):1397-1404.

(126) Naor D, Morecki S, Mitchell GF. Differential induction of anti‐trinitrophenyl plaque‐forming cell responses to lightly and heavily conjugated trinitrophenylated heterologous and autologous erythrocytes in mice. Eur J Immunol 1974;4(4):311-314.

(127) Naor D, Morecki S, Kedar E. Differential induction and suppression of direct and indirect PFC responses to TNP conjugated to heterologous erythrocytes. Adv Exp Med Biol 1973;29:225-232.

(128) Naor D, Mishell R. In vitro immunity to TNP and penicillin: specific inhibition with hapten-conjugated isologous red cells. J Immunol 1972;108(1):246-252.

(129) Naor D, Henry C, Fudenberg HH. An in vitro immune response to penicillin. J Immunol 1971;107(1):302-305.

(130) Wofsy L, Truffa‐Bachi P, Naor D. CHEMICAL APPROACHES TO THE CELL RECEPTOR PROBLEM. Ann New York Acad Sci 1971;190(1):432-442.

(131) Naor D, Mishell RI, Wofsy L. Specific inhibition of an anti-hapten immune response by chemical modifications of cells. J Immunol 1970;105(6):1322-1326.

(132) Naor D, Sulitzeanu D. Affinity of radioiodinated bovine serum albumin for lymphoid cells. 3. Further experiments with cells of normal animals. Isr J Med Sci 1970;6(4):519-522.

(133) Naor D, Sulitzeanu D. Affinity of radioiodinated bovine serum albumin for lymphoid cells. Binding of I-125-BSA to lymphoid cells of immune mice. Isr J Med Sci 1969;5(2):217-229.

(134) Naor D, Sulitzeanu D. Binding of 125I-BSA to lymphoid cells of tolerant mice. Int Arch Allergy Appl Immunol 1969;36(1):112-113.

(135) Sulitzeanu D, Naor D. The affinity of radioiodinated BSA for lymphoid cells. II. Binding of 125I-BSA to lymphoid cells of normal mice. Int Arch Allergy Appl Immunol 1969;35(6):564-578.

(136) Naor D, Bentwich Z, Cividalli G. Inability of peripheral lymphoid cells of agammaglobulinaemic patients to bind radioiodinated albumins. Aust J Exp Biol Med Sci 1969;47(6):759-761.

(137) Naor D, Sulitzeanu D. Binding of radioiodinated bovine serum albumin to lymphoid cells of specifically primed or immunized mice in vitro. Life Sci 1968;7(8 PART 2):377-382.

(138) Naor D, Sulitzneau D. Binding of radioiodinated bovine serum albumin to mouse spleen cells. Nature 1967;214(5089):687-688.